Skip to main content

Table 2 Lesion and procedural characteristics

From: Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes

 

Overall

BP-SES

DP-EES

p value

n = 165

n = 48

n = 117

Target vessel, n (%)

0.254

 Left main trunk

7 (4.2)

1 (2.1)

6 (5.1)

 Left anterior descending artery

86 (52.1)

25 (52.1)

61 (52.1)

 Left circumflex artery

20 (12.1)

3 (6.2)

17 (14.5)

 Right coronary artery

52 (31.6)

19 (39.6)

33 (28.3)

Type B2/C lesion, n (%)

92 (55.8)

30 (62.5)

62 (53.0)

0.264

QCA pre PCI

 Lesion length, mm

22.6 (12.7–35.1)

21.3 (12.2–37.9)

23.9 (13.5–35.0)

0.401

 Reference vessel diameter, mm

2.48 (2.07–2.98)

2.45 (2.11–2.81)

2.48 (2.06–3.02)

0.649

 Minimum lumen diameter, mm

0.87 (0.45–1.22)

0.78 (0.51–1.01)

0.91 (0.42–1.30)

0.410

 Diameter stenosis, %

64 (51–80)

69 (58–80)

63 (50–80)

0.405

QCA post PCI

 Reference vessel diameter, mm

2.63 (2.34–3.02)

2.67 (2.43–3.10)

2.60 (2.26–3.01)

0.321

 Minimum lumen diameter, mm

2.30 (2.02–2.60)

2.39 (2.05–2.75)

2.26 (2.01–2.57)

0.216

 Diameter stenosis, %

11 (5–18)

11 (5–17)

12 (5–18)

0.624

Rotational atherectomy, n (%)

12 (7.3)

2 (4.2)

10 (8.6)

0.325

Bifurcation, n (%)

38 (23.0)

13 (27.1)

25 (21.4)

0.428

Chronic total occlusion, n (%)

17 (10.3)

4 (8.3)

13 (11.1)

0.594

Imaging device, n (%)

165 (100)

48 (100)

117 (100)

–

Number of stents, n

1 (1–2)

2 (1–2)

1 (1–2)

0.100

Total stent length, mm

33 (23–56)

37 (27–62)

33 (21–54)

0.134

Minimum stent diameter, mm

2.75 (2.5–3.0)

2.5 (2.5–3.0)

2.75 (2.5–3.0)

0.468

  1. BP-SES biodegradable polymer sirolimus-eluting stent, DP-EES durable polymer everolimus-eluting stent, PCI percutaneous coronary intervention, QCA quantitative coronary angiography